New Economic Study: Dapagliflozin Cost-Effective in Kidney Disease

Dapagliflozin is cost-effective for chronic kidney disease compared with standard of care, in the UK, Germany, and Spain, despite the fact that the drug has high acquisition costs, finds a new analysis.
Medscape Medical News

source https://www.medscape.com/viewarticle/983768?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension